MedTrace Logo

Pseudophakic Astigmatic Reduction With Verion-LenSx Arcuate Incisions

NCT02763124 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2019-11-01

Study results available
· View outcomes & findings →

Summary

To assess the effectiveness of the Verion-LenSx guided arcuate incision technique to reduce astigmatism in a pseudophakic population.

Conditions

  • Astigmatism

Interventions

PROCEDURE

Verion-LenSx

The Verion-LenSx femtosecond laser system will be used to create one or two partial-depth corneal arcuate incisions

Sponsors & Collaborators

  • Alcon, a Novartis Company

    collaborator INDUSTRY

  • Gainesville Eye Associates

    lead OTHER

Principal Investigators

  • Clayton Blehm, MD · Gainesville Eye Associates

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02763124 on ClinicalTrials.gov